Shares of French biotech Quantum Genomics (Euronext Growth: ALQGC) were decimated on Friday after its revealed efficacy results for firibastat in its Phase III study FRESH in treatment-resistant hypertension (TRH), are non-significant versus placebo. The stock plunged 90% to 0.33 euros.
As a result, the company has terminated a second, longer-term Phase III trial (REFRESH) in TRH and will stop the development of firibastat in cardiology. The company will now focus on the development of new, undisclosed treatments.
Quantum Genomics’ long-term strategy rested on firibastat’s success in TRH. However, the discontinuation of clinical activities will leave the company with a not insignificant cash position (11 million euros) with which to acquire or license new assets for development, noted analysts at Edison Research.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze